6-K: Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments
Published on February 14, 2019
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934
| For the month of: February 2019 | Commission File Number: 001-35776 |
ACASTI PHARMA INC.
(Name of Registrant)
545 Promende du Centropolis
Suite 100
Laval, Québec
Canada H7T 0A3
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ¨
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ACASTI PHARMA INC. | ||
| Date: February 14, 2019 | By: | /s/ Jan D'Alvise |
|
Name: Jan D'Alvise Title: Chief Executive Officer |
EXHIBIT INDEX
| Exhibit | Description of Exhibit |
| 99.1 | Sales Agreement, dated February 14, 2019, between Acasti Pharma Inc. and B. Riley FBR, Inc. |
| 99.2 | Opinion of Osler, Hoskin & Harcourt LLP |